Prostate cancer: local control and radiotherapy matter in prostate cancer.
In a study published in The Lancet, long-term androgen suppression (AS) combined with radiotherapy, compared with AS alone, improved outcomes in patients with locally advanced but nonmetastatic prostate cancer. The combined therapy significantly reduced prostate-cancer-specific deaths at 10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.